SynthesisESC heart failure2022
Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas.
Synthesis in ESC heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas.ESC heart failure · 2022Pooled it
- Burden of heart failure in Asian Countries from 1990 to 2021: Update from the Global Burden of Disease Study 2021.PloS one · 2026Article
- Obesity Is Associated with a Lower Risk of Mortality and Readmission in Heart Failure Patients with Diabetes.Biomedicines · 2025Article
- Changes in heart failure healthcare in general practice during the COVID-19 pandemic: a survey.BJGP open · 2025Article
- Global, regional, and national burden of heart failure and its underlying causes, 1990-2021: results from the global burden of disease study 2021.Biomarker research · 2025Article
- The Impact of Vaccinations Against Respiratory Infections on the Prognosis in Heart Failure Patients.Vaccines · 2024Review
- Deciphering heart failure: an integrated proteomic and transcriptomic approach with experimental validation.Functional & integrative genomics · 2024Article
- Myocarditis Associated with COVID-19 Vaccination.Vaccines · 2024Review
- Primary Cardiac Intimal Sarcoma: Multi-Layered Strategy and Core Role ofDiagnostics (Basel, Switzerland) · 2024Review
- Revascularization and Left Ventricular Dysfunction for ICD Eligibility.Life (Basel, Switzerland) · 2023Review
- Telemedicine in Heart Failure in the COVID-19 and Post-Pandemic Era: What Have We Learned?Biomedicines · 2023Review
- A year in heart failure: updates of clinical and preclinical findings.ESC heart failure · 2023Review
- Factors Affecting Referral and Patient Access to Heart Function Clinics in Ontario: A Qualitative Study of Stakeholders.CJC open · 2023Article
- Acute COVID-19 Management in Heart Failure Patients: A Specific Setting Requiring Detailed Inpatient and Outpatient Hospital Care.Biomedicines · 2023Review
- Article
- Pathophysiological effects of SARS-CoV-2 infection on the cardiovascular system and its clinical manifestations-a mini review.Frontiers in cardiovascular medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 17 institutions in 16 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus 2019 (COVID-19) infection pandemic has affected the care of patients with heart failure (HF). Several consensus documents describe the appropriate diagnostic algorithm and treatment approach for patients with HF and associated COVID-19 infection. However, few questions about the mechanisms by which COVID can exacerbate HF in patients with high-risk (Stage B) or symptomatic HF (Stage C) remain unanswered. Therefore, the type of HF occurring during infection is poorly investigated. The diagnostic differentiation and management should be focused on the identification of the HF phenotype, underlying causes, and subsequent tailored therapy. In this framework, the relationship existing between COVID and onset of acute decompensated HF, isolated right HF, and cardiogenic shock is questioned, and the specific management is mainly based on local hospital organization rather than a standardized model. Similarly, some specific populations such as advanced HF, heart transplant, patients with left ventricular assist device (LVAD), or valve disease remain under investigated. In this systematic review, we examine recent advances regarding the relationships between HF and COVID-19 pandemic with respect to epidemiology, pathogenetic mechanisms, and differential diagnosis. Also, according to the recent HF guidelines definition, we highlight different clinical profile identification, pointing out the main concerns in understudied HF populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.